Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer
Name:
36303830.pdf
Size:
1.098Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Banfill, KathrynAbravan, Azadeh
van Herk, Marcel
Sun, F.
Franks, K.
McWilliam, Alan
Faivre-Finn, Corinne
Affiliation
Department of Clinical Oncology, The Christie National Health Service (NHS) Foundation Trust, ManchesterIssue Date
2022
Metadata
Show full item recordAbstract
Background: There is increasing evidence of cardiac toxicity of thoracic radiotherapy however, it is difficult to draw conclusions on cardiac dose constraints due to the heterogeneity of published studies. Moreover, few studies record data on cause of death. The aim of this paper is to investigate the relationship between conventional cardiac dosimetric parameters and death with cardiac causes using data from the UK national cause of death registry. Methods: Data on cancer diagnosis, treatment and cause of death following radical lung cancer radiotherapy were obtained from Public Health England for all patients treated at the Christie NHS Foundation Trust between 1/1/10 and 31/12/16. Individuals with metastatic disease and those who received multiple courses of thoracic radiotherapy where excluded. All patients who received > 45Gy in 20 fractions were included. Cardiac cause of death was defined as the following ICD-10 codes on death certificate: I20-I25; I30-I32; I34-I37; I40-I52. Cardiac V5Gy, V30Gy, V50Gy and mean heart dose (MHD) were extracted. Cumulative incidence of death with cardiac causes were plotted for each cardiac dosimetric parameter. Multi-variable Fine and Gray competing risk analysis was used to model predictors for cardiac death with non-cardiac death as a competing risk. Results: Cardiac dosimetric parameters were available for 967 individuals, 110 died with a cardiac cause (11.4%). Patients with a cardiac comorbidity had an increased risk of death with a cardiac cause compared with those without a cardiac comorbidity (2-year cumulative incidence 21.3% v 6.2%, p<0.001). In patients with a pre-existing cardiac comorbidity, heart V30Gy ≥ 15% was associated with higher cumulative incidence of death with a cardiac cause compared to patients with heart V30Gy <15% (2-year rate 25.8% v 17.3%, p=0.05). In patients without a cardiac comorbidity, after adjusting for tumour and cardiac risk factors, MHD (aHR 1.07, 1.01-1.13, p=0.021), heart V5Gy (aHR 1.01, 1-1.13, p=0.05) and heart V30Gy (aHR 1.04, 1-1.07, p=0.039) were associated with cardiac death. Conclusion: The effect of cardiac radiation dose on cardiac-related death following thoracic radiotherapy is different in patients with and without cardiac comorbidities. Therefore patients' cardiovascular risk factors should be identified and managed alongside radiotherapy for lung cancer.Citation
Banfill K, Abravan A, van Herk M, Sun F, Franks K, McWilliam A, et al. Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer. Frontiers in oncology. 2022;12:1007577. PubMed PMID: 36303830. Pubmed Central PMCID: PMC9592751. Epub 2022/10/29. eng.Journal
Frontiers in OncologyDOI
10.3389/fonc.2022.1007577PubMed ID
36303830Additional Links
https://dx.doi.org/10.3389/fonc.2022.1007577Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3389/fonc.2022.1007577
Scopus Count
Collections
Related articles
- Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer.
- Authors: Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, Kozono DE, Baldini EH, Chen AB, Nguyen PL, D'Amico AV, Nohria A, Hoffmann U, Aerts HJWL, Mak RH
- Issue date: 2019 Jun 18
- Impact of Low-Dose Irradiation of the Lung and Heart on Toxicity and Pulmonary Function Parameters after Thoracic Radiotherapy.
- Authors: Schröder C, Buchali A, Windisch P, Vu E, Basler L, Zwahlen DR, Förster R
- Issue date: 2020 Dec 23
- Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy.
- Authors: Atkins KM, Bitterman DS, Chaunzwa TL, Kozono DE, Baldini EH, Aerts HJWL, Tamarappoo BK, Hoffmann U, Nohria A, Mak RH
- Issue date: 2021 Aug 1
- Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study).
- Authors: Jacob S, Camilleri J, Derreumaux S, Walker V, Lairez O, Lapeyre M, Bruguière E, Pathak A, Bernier MO, Laurier D, Ferrieres J, Gallocher O, Latorzeff I, Pinel B, Franck D, Chevelle C, Jimenez G, Broggio D
- Issue date: 2019 Feb 7
- Cardiac substructures exposure in left-sided breast cancer radiotherapy: Is the mean heart dose a reliable predictor of cardiac toxicity?
- Authors: Naimi Z, Moujahed R, Neji H, Yahyaoui J, Hamdoun A, Bohli M, Kochbati L
- Issue date: 2021 May